Education
About Us
Working with TipRanks
Follow Us
Orasure Technologies (OSUR)
NASDAQ:OSUR
OSUR Stock Chart & Stats
$2.38
-$0.09(-2.38%)
At close: 4:00 PM EST
$2.38
-$0.09(-2.38%)
Day’s Range― - ―
52-Week Range$2.08 - $4.22
Previous CloseN/A
Volume226.53K
Average Volume (3M)771.42K
Market Cap
$213.77M
Enterprise Value$219.94M
Total Cash (Recent Filing)$199.28K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.71
Next Earnings
May 13, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding71,733,530
10 Day Avg. Volume735,713
30 Day Avg. Volume771,421
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.52
Price to Sales (P/S)1.55
P/FCF Ratio-3.34K
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue1.91
Enterprise Value/Gross Profit5.01
Enterprise Value/Ebitda-3.52
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$118.95M
Bulls Say, Bears Say
Bulls Say
Strong Cash Position & Zero DebtA $199M cash balance with no debt provides a durable liquidity buffer to fund R&D, regulatory reviews, and commercialization efforts without immediate financing pressure. Coupled with active buybacks, this balance sheet flexibility supports multi-year product development and gives management optionality to absorb near-term cash burn while pursuing the H2 2026 ramp.
Near-term FDA Product CatalystsRegulatory submissions for an OTC CT/NG molecular self-test and an at‑home urine collection device, if cleared, structurally expand access to decentralized STI testing and address a large TAM (> $1.5B). Successful approvals would diversify revenues away from lab-centric channels and create a sustainable growth vector through durable market expansion and new distribution models.
Manufacturing Consolidation And Margin LeverageConsolidating manufacturing and internalizing most sample management volumes meaningfully increases fixed‑cost absorption potential. With operations currently underoccupied, any sustained volume recovery should yield durable gross‑margin expansion through higher capacity utilization and lower outsourcing costs, supporting margin sustainability as revenue scales.
Bears Say
Sharp Revenue Decline And Lost ProfitabilityA steep decline in revenue and a shift from solid 2023 profits to multi-year losses indicate a structural erosion of scale. Reduced top‑line weakens the firm’s ability to cover fixed costs and maintain R&D and commercial investments, extending the timeline to sustainable margins and increasing sensitivity to execution on new product launches.
Negative Operating Cash Flow And Multi‑year Burn RiskNegative operating cash flow and a multi‑year path to breakeven create persistent cash‑burn risk. Even with a large cash balance today, continued negative OCF forces reliance on either rapid commercial execution or external financing, limiting long‑term strategic flexibility and increasing downside if regulatory or market ramps slip.
Regulatory And Funding Execution RiskRevenue recovery depends on timely FDA approvals and stable international public‑health funding. Regulatory review delays or recurring funding disruptions materially postpone the expected H2 2026 ramp, prolong underutilized capacity, and jeopardize the company’s ability to convert product catalysts into sustained revenue and margin improvements.
Orasure Technologies News
OSUR FAQ
What was Orasure Technologies’s price range in the past 12 months?
Orasure Technologies lowest stock price was $2.08 and its highest was $4.22 in the past 12 months.
What is Orasure Technologies’s market cap?
Orasure Technologies’s market cap is $213.77M.
When is Orasure Technologies’s upcoming earnings report date?
Orasure Technologies’s upcoming earnings report date is May 13, 2026 which is in 69 days.
How were Orasure Technologies’s earnings last quarter?
Orasure Technologies released its earnings results on Feb 25, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.205 by -$0.065.
Is Orasure Technologies overvalued?
According to Wall Street analysts Orasure Technologies’s price is currently Overvalued.
Does Orasure Technologies pay dividends?
Orasure Technologies does not currently pay dividends.
What is Orasure Technologies’s EPS estimate?
Orasure Technologies’s EPS estimate is -0.22.
How many shares outstanding does Orasure Technologies have?
Orasure Technologies has 71,733,530 shares outstanding.
What happened to Orasure Technologies’s price movement after its last earnings report?
Orasure Technologies reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.205. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Orasure Technologies?
Currently, no hedge funds are holding shares in OSUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orasure Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
OSUR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 14.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.53%
12-Months-Change
Fundamentals
Return on Equity
-15.30%
Trailing 12-Months
Asset Growth
-8.83%
Trailing 12-Months
Company Description
Orasure Technologies
OraSure Technologies, Inc. is a leader in the field of oral fluid diagnostics and medical devices, primarily focusing on the development and sale of products for the detection of infectious diseases and for drug testing. The company operates in two main sectors: the infectious disease testing market and the substance abuse testing market. Its core products include rapid diagnostic tests for HIV, HCV, and other infectious diseases, as well as oral fluid collection devices used for drug testing and other applications.
OSUR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights clear progress on strategic priorities: revenue slightly beat guidance midpoint, meaningful improvement in gross margins year-over-year, strong cash position with no debt, two significant FDA submissions targeting midyear launches, tangible international expansion (Canada launch, nearshoring in Africa) and early success integrating BiMedomics. Offsetting these positives are sizable operating losses and negative operating cash flow, a multi-year timeline to return to operating cash flow breakeven (target 2027), lingering funding-related headwinds in international public-health markets, regulatory timing uncertainty for new product launches, and under-utilized capacity that makes margin improvement contingent on revenue ramp. Overall, the call conveys cautious optimism grounded in a solid balance sheet and promising near-term product catalysts but tempered by execution risk and the need for top-line recovery to fully realize margin and cash-flow benefits.View all OSUR earnings summariesTechnical Analysis
InfuSystem Holdings
―
Stereotaxis
―
Utah Medical Products
―
Microbot Medical
―
Sanara MedTech
―
Ownership Overview
4.42% Insiders
16.53% Mutual Funds
31.66% Other Institutional Investors
35.18% Public Companies and
Individual Investors